A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.
Also called NCT03697109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 152 participants
- Sponsor
- Registry
-
NCT03697109
-
- Other papers using this trial's data
- Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03697109. Randomized; triple masking; primary purpose treatment. Start 2018-11-15 (actual); primary completion 2024-04-08 (actual). Results posted on 2025-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- Acronym
- GRACE
- Condition
- Cushing Syndrome
- Intervention (Drug)
- Relacorilant
- Intervention (Other)
- Placebo
- Lead sponsor
- Corcept Therapeutics
Record details
- Record id
cardio:ct-nct03697109- Content hash
12f194b3d21e89c0f80e089472f8d433f06519ee1907611340a789025968daa6